ICH Moves Q7 Q&A Guideline on APIs to Implementation Stage

Article

The International Conference on Harmonization finalizes Q&A document on APIs.

 

The International Conference on Harmonization (ICH) announced on June 19, 2015 that Q7 Guideline: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients, Questions and Answers has reached Step 4 of the process and now enters into Step 5, the implementation stage. The Q&A document addresses confusion regarding interpretation of the Q7 guideline and aims to harmonize expectations during inspections of both small molecules and biotech APIs.

Topics clarified in the Q&A document are varied. The following are some of the answers ICH provides:

  • Quality management. ICH addresses questions on the meaning of 'quality unit(s) independent from production'; expectations of the quality unit regarding API release testing and sampling; and product quality reviews.

  • Personnel. Answers to questions regarding personnel include assessment of training; the use of consultants; and dedicated production areas.

  • Buildings and facilities. ICH clarifies confusion about dedicated production areas and the use of quality risk management.

  • Equipment cleaning. Questions regarding the cleaning of process equipment address the acceptance of the term ‘visually clean’; acceptance criteria for residues; cleaning time limits; cleaning validation; and product changeover.

  • Record keeping. ICH clarifies record retention; batch numbering systems; and batch production records.

  • Materials management. A number of items are clarified regarding materials management, including supplier evaluations, on-site audits of suppliers, identity tests, and expiry dates.

Other topics discussed include production and in-process controls; storage and distribution; laboratory controls; validation; change control; and contract manufacturers.

The Q7 Q&A document can be found on ICH’s guideline webpage.

Source: ICH.org

Recent Videos
Behind the Headlines episode 8
Christian Dunne, director of Global Corporate Business Development at ChargePoint Technology
Roger Viney, PhD, chief commercial officer for ICE Pharma
Roger Viney, PhD, chief commercial officer for ICE Pharma
Related Content